These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 27573564)

  • 1. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
    Ikeda M; Shimizu S; Sato T; Morimoto M; Kojima Y; Inaba Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T
    Ann Oncol; 2016 Nov; 27(11):2090-2096. PubMed ID: 27573564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.
    Hagihara A; Ikeda M; Ueno H; Morizane C; Kondo S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Suzuki E; Katayama K; Imanaka K; Tamai C; Inaba Y; Sato Y; Kato M; Okusaka T
    Cancer Sci; 2014 Mar; 105(3):354-8. PubMed ID: 24438504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
    Koeberle D; Dufour JF; Demeter G; Li Q; Ribi K; Samaras P; Saletti P; Roth AD; Horber D; Buehlmann M; Wagner AD; Montemurro M; Lakatos G; Feilchenfeldt J; Peck-Radosavljevic M; Rauch D; Tschanz B; Bodoky G;
    Ann Oncol; 2016 May; 27(5):856-61. PubMed ID: 26884590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
    Ciuleanu T; Bazin I; Lungulescu D; Miron L; Bondarenko I; Deptala A; Rodriguez-Torres M; Giantonio B; Fox NL; Wissel P; Egger J; Ding M; Kalyani RN; Humphreys R; Gribbin M; Sun W
    Ann Oncol; 2016 Apr; 27(4):680-7. PubMed ID: 26802147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
    Sanoff HK; Chang Y; Lund JL; O'Neil BH; Dusetzina SB
    Oncologist; 2016 Sep; 21(9):1113-20. PubMed ID: 27185615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
    Lee FA; Zee BC; Cheung FY; Kwong P; Chiang CL; Leung KC; Siu SW; Lee C; Lai M; Kwok C; Chong M; Jolivet J; Tung S
    Am J Clin Oncol; 2016 Dec; 39(6):609-613. PubMed ID: 24977690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
    He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
    Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
    Zhu AX; Rosmorduc O; Evans TR; Ross PJ; Santoro A; Carrilho FJ; Bruix J; Qin S; Thuluvath PJ; Llovet JM; Leberre MA; Jensen M; Meinhardt G; Kang YK
    J Clin Oncol; 2015 Feb; 33(6):559-66. PubMed ID: 25547503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma.
    Ishizaki M; Kaibori M; Matsui K; Ikeda H; Yoshida K; Okazaki K; Kariya S; Tanigawa N; Nakatake R; Matsushima H; Sakaguchi T; Kon M
    Cancer Invest; 2017 Apr; 35(4):271-276. PubMed ID: 28272913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib in liver function impaired advanced hepatocellular carcinoma.
    Ji YX; Zhang ZF; Lan KT; Nie KK; Geng CX; Liu SC; Zhang L; Zhuang XJ; Zou X; Sun L; Zhang ZC
    Chin Med Sci J; 2014 Mar; 29(1):7-14. PubMed ID: 24698672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
    Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
    Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial.
    Kamimura K; Suda T; Yokoo T; Kamimura H; Kanefuji T; Tsuchiya A; Takamura M; Kawai H; Waguri N; Yamagiwa S; Terai S
    BMC Cancer; 2017 May; 17(1):322. PubMed ID: 28490356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
    Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
    J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
    J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.